Northwest Biotherapeutics (OTCMKTS: NWBO) stock experienced a short rise and fall process in the middle of last month. Although the stock fell by 2.5% so far this year, it is trying to recover.
(Image source: Northwest Biotherapeutics website)
Last month, this biotechnology company announced that it has submitted an application to the Medicines and Healthcare Products Regulatory Agency for certification of the manufacturing facility in Sawston, UK.
The Sawston facility will produce good manufacturing practice clinical grade medical products for patients. The company hopes that an initial license will be issued and production of its lead product, DCVax-L in this facility by around the end of Q3.
DCVax-L is used for glioblastoma multiforme, the most lethal form of primary brain cancer and is now well under way with a large Phase 3 trial. The company anticipates that trial results will be ready for reporting approximately sometime after Labor Day in the month of September. Therefore, the stock is worth tracking for investors who focus on biotechnology sector for a long time.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.